FR0004163111 - Common Stock

Taking everything into account, **GNFT** scores **4** out of 10 in our fundamental rating. **GNFT** was compared to 74 industry peers in the **Biotechnology** industry. **GNFT** may be in some trouble as it scores bad on both profitability and health. **GNFT** is growing strongly while it is still valued neutral. This is a good combination!

In the past 5 years **GNFT** reported 4 times negative operating cash flow.

The **Return On Assets** of **GNFT** (**-16.62%**) is better than **70.00%** of its industry peers.

The **Return On Equity** of **GNFT** (**-42.52%**) is better than **61.43%** of its industry peers.

Industry Rank | Sector Rank | ||
---|---|---|---|

ROA | -16.62% | ||

ROE | -42.52% | ||

ROIC | N/A |

ROA(3y)-1.25%

ROA(5y)-15.15%

ROE(3y)-3.71%

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

Looking at the **Gross Margin**, with a value of **94.32%**, **GNFT** belongs to the top of the industry, outperforming **90.00%** of the companies in the same industry.

Industry Rank | Sector Rank | ||
---|---|---|---|

OM | N/A | ||

PM (TTM) | N/A | ||

GM | 94.32% |

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y8.81%

GM growth 5Y4.62%

The number of shares outstanding for **GNFT** remains at a similar level compared to 1 year ago.

The number of shares outstanding for **GNFT** has been increased compared to 5 years ago.

Compared to 1 year ago, **GNFT** has a worse debt to assets ratio.

With a **Altman-Z score** value of **-1.72**, **GNFT** is not doing good in the industry: **60.00%** of the companies in the same industry are doing better.

A Debt/Equity ratio of **0.92** indicates that **GNFT** is somewhat dependend on debt financing.

Industry Rank | Sector Rank | ||
---|---|---|---|

Debt/Equity | 0.92 | ||

Debt/FCF | N/A | ||

Altman-Z | -1.72 |

ROIC/WACCN/A

WACC7.43%

The **Current ratio** of **GNFT** (**2.94**) is better than **65.71%** of its industry peers.

A Quick Ratio of **2.94** indicates that **GNFT** has no problem at all paying its short term obligations.

Industry Rank | Sector Rank | ||
---|---|---|---|

Current Ratio | 2.94 | ||

Quick Ratio | 2.94 |

The earnings per share for **GNFT** have decreased strongly by **-21.75%** in the last year.

EPS 1Y (TTM)-21.75%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%40.74%

Revenue 1Y (TTM)43.7%

Revenue growth 3Y70.09%

Revenue growth 5Y38.49%

Sales Q2Q%18.81%

Based on estimates for the next years, **GNFT** will show a very strong growth in **Revenue**. The Revenue will grow by **27.66%** on average per year.

EPS Next Y303.9%

EPS Next 2Y-73.62%

EPS Next 3Y44.37%

EPS Next 5YN/A

Revenue Next Year67.79%

Revenue Next 2Y-11.44%

Revenue Next 3Y-0.49%

Revenue Next 5Y27.66%

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.

The **Price/Earnings Ratio** is negative for **GNFT**. In the last year negative earnings were reported.

The **Price/Forward Earnings** ratio is **12.74**, which indicates a correct valuation of **GNFT**.

Compared to the rest of the industry, the **Price/Forward Earnings** ratio of **GNFT** indicates a rather cheap valuation: **GNFT** is cheaper than 85.71% of the companies listed in the same industry.

Compared to an average S&P500 **Price/Forward Earnings** ratio of **20.94**, **GNFT** is valued a bit cheaper.

Industry Rank | Sector Rank | ||
---|---|---|---|

PE | N/A | ||

Fwd PE | 12.74 |

Industry Rank | Sector Rank | ||
---|---|---|---|

P/FCF | N/A | ||

EV/EBITDA | N/A |

A more expensive valuation may be justified as **GNFT**'s earnings are expected to grow with **44.37%** in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-73.62%

EPS Next 3Y44.37%

Industry Rank | Sector Rank | ||
---|---|---|---|

Dividend Yield | N/A |

**GENFIT**

EPA:GNFT (7/17/2024, 11:36:25 AM)

**4.2**

**0 (0%) **

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap209.42M

Analysts

Price Target

Dividend

Industry Rank | Sector Rank | ||
---|---|---|---|

Dividend Yield | N/A |

Dividend Growth(5Y)

DP

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

Industry Rank | Sector Rank | ||
---|---|---|---|

PE | N/A | ||

Fwd PE | 12.74 | ||

P/S | |||

P/FCF | |||

P/OCF | |||

P/B | |||

P/tB | |||

EV/EBITDA |

EPS(TTM)

EY

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

Industry Rank | Sector Rank | ||
---|---|---|---|

ROA | -16.62% | ||

ROE | -42.52% | ||

ROCE | |||

ROIC | |||

ROICexc | |||

ROICexgc | |||

OM | N/A | ||

PM (TTM) | N/A | ||

GM | 94.32% | ||

FCFM |

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.22

Health

Industry Rank | Sector Rank | ||
---|---|---|---|

Debt/Equity | 0.92 | ||

Debt/FCF | |||

Debt/EBITDA | |||

Cap/Depr | |||

Cap/Sales | |||

Interest Coverage | |||

Cash Conversion | |||

Profit Quality | |||

Current Ratio | 2.94 | ||

Quick Ratio | 2.94 | ||

Altman-Z |

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

High Growth Momentum

Growth

EPS 1Y (TTM)-21.75%

EPS 3YN/A

EPS 5Y

EPS Q2Q%

EPS Next Y303.9%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)43.7%

Revenue growth 3Y70.09%

Revenue growth 5Y

Sales Q2Q%

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y